Join
Live feed
·
PRReleasevia Quantisnow
Phathom Pharmaceuticals Inc. logo

Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD

ByQuantisnow·Wall Street's wire, on your screen.
PHAT· Phathom Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PHAT (Phathom Pharmaceuticals Inc.) and more on Quantisnow.